Biocytogen Announces 16 Poster Presentations and Booth Exhibition at SITC 2023

BEIJING & WALTHAM, Mass.–(BUSINESS WIRE)–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) announced today that the company will be presenting 16 posters and exhibiting at booth 223 at the Society for Immunotherapy of Cancer (SITC) annual conference, taking place from November 1-5, 2023 in San Diego, CA.

The poster presentations will highlight 9 drug assets and 7 gene-edited humanized mouse models:

Bispecific Antibody-Drug Conjugate Assets

DM001: A novel bispecific ADC targeting TROP2 and EGFR with potent anti-tumor efficacy in PDX models

Poster number: 1152

Date: November 4th, 2023

Preclinical evaluation of fully human bispecific antibody-drug candidates targeting HER3 and the juxtamembrane region of MUC1

Poster number: 1165

Date: November 3rd, 2023

DM005, an EGFR х MET bispecific antibody-drug conjugate, showed robust anti-tumor activity in PDX models

Poster number: 1150

Date: November 4th, 2023

BSA01, a bispecific antibody-drug conjugate targeting EGFR and membrane-bound MUC-1-C, exhibits anti-tumor efficacy in vivo

Poster number: 1164

Date: November 4th, 2023

BCG022: A HER3×MET bispecific antibody-drug conjugate (BsADC) targeting key mechanisms of bypass resistance in multiple tumor types

Poster number: 1153

Date: November 3rd, 2023

A novel bispecific antibody-drug conjugate targeting PTK7 and TROP2, BCG033, demonstrates preclinical efficacy against triple-negative breast cancer xenografts

Poster number: 1163

Date: November 3rd, 2023

TCR-mimic Antibody Assets

Identification of fully human TCR-mimic antibodies targeting the KRAS G12V/HLA complex generated in HLA-transgenic RenMab™ mice

Poster number: 1168

Date: November 4th, 2023

Preclinical application of a fully human TCR-mimic antibody developed to target NY-ESO-1/HLA-A02

Poster number: 356

Date: November 4th, 2023

Fully Human Monoclonal Antibody Asset

Fc-competent fully human anti-TIGIT blocking monoclonal antibodies demonstrated potent anti-tumor efficacy in preclinical models

Poster number: 479

Date: November 3rd, 2023

Off-the-Shelf Mouse Models – Humanized Mice

Development of a preclinical CD98HC mouse model for therapeutic studies

Poster number: 13

Date: November 3rd, 2023

Generation and validation of humanized GARP/TGFB1 mice for testing novel anti-human GARP antibodies

Poster number: 18

Date: November 4th, 2023

Humanized CD200/CD200R mice as a tool for evaluating novel therapeutics

Poster number: 12

Date: November 4th, 2023

Humanized ICOS mice as a novel tool for predicting and monitoring T-cell-mediated immunotherapy response

Poster number: 11

Date: November 3rd, 2023

Humanized NKP46 mouse models for testing novel NK cell-based immunotherapies

Poster number: 17

Date: November 3rd, 2023

Preclinical CD3-based mouse models for evaluation of bi-specific T-cell engager antibodies

Poster number: 19

Date: November 3rd, 2023

Off-the-Shelf Mouse Models – Immunodeficient Target Humanized Mice

A novel B2m-deficient immunodeficient model expressing human IL-15 for preclinical evaluation of T cell and NK cell-based therapies

Poster number: 16

Date: November 4th, 2023

To explore licensing and collaboration opportunities for drug assets, fully human antibody/TCR discovery platforms, off-the-shelf animal/cell models, or preclinical pharmacology services, please visit booth 223.

About Biocytogen

Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMab™/RenLite^®/RenNano^® mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum (RenMice^® HiTS Platform). As of June 30, 2023, 50 therapeutic antibody co-development/out-licensing/transfer agreements and 42 target-nominated RenMice^® licensing projects have been established worldwide, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen’s pipeline is comprised of 10 core assets, with partnerships established for multiple clinical assets. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.

Contacts

Biocytogen
Antibody Therapeutic R&D: BD-Licensing@biocytogen.com
BioMice models and preclinical services: info@biocytogen.com
Media: pr@bbctg.com.cn